The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.’s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
The major regulatory milestone marks a significant advancement for individuals suffering from this rare and debilitating autoimmune condition, which causes severe inflammation and tissue remodeling around the eyes.
The company is preparing for an immediate commercial rollout.
Lumvoq’s FDA approval represents a key inflection point for Viridian, as the company moves from development-stage to commercial operations with its first approved therapy.
Rapid Launch And Patient Access Support
Viridian intends to launch the treatment immediately, and the biotechnology firm has collaborated closely with healthcare providers, insurance payers, and various patient advocacy groups.
The immediate commercial launch is further backed by a comprehensive patient support initiative designed to help navigate treatment availability.
Clinical Trial Success For Active And Chronic Patients
The regulatory agency approved a Priority Review designation based on data from two pivotal Phase 3 clinical trials: THRIVE, which evaluated patients with active TED, and THRIVE-2, which focused on chronic variations of the illness.
Lumvoa acts as a full antagonist of IGF-1R. Notably, it stands as the initial approved therapy for thyroid eye disease to feature official labeling data encompassing both active and chronic forms of the condition.
Both clinical trials successfully achieved all primary and secondary endpoints, demonstrating statistically significant and clinically meaningful health improvements by the 15th week.
Reduced Treatment Burden And Efficacy Rates
Patients across both clinical studies underwent a specialized 12-week regimen engineered specifically to minimize the overall burden of treatment.
The therapy demonstrated a rapid onset of clinical benefits, with noticeable reductions in proptosis recorded as early as three weeks into the program.
Furthermore, Lumvoa represents the first approved medication for thyroid eye disease to exhibit a statistically significant impact on diplopia response, alongside complete resolution in both active and chronic patient groups.
Analyst Sees Market Share Opportunity
William Blair on Monday wrote, “We believe Lumvoa has the potential to capture meaningful market share from Amgen Inc.’s (NASDAQ:AMGN) Tepezza (teprotumumab), supported by its competitive clinical profile across both active and chronic TED populations, with potential for modest market expansion.”
Analyst Lachlan Hanbury-Brown said Viridian’s elegrobart remains on track for a BLA filing in the first quarter of 2027 and is well-positioned to expand into the chronic patient population.
He added that the therapy could emerge as a leading option for chronic TED patients, supported by its convenient subcutaneous administration and strong clinical profile.
Combined with Viridian’s broader portfolio, elegrobart could help the company target multiple patient segments and strengthen its long-term position in the TED market.
VRDN Stock Price Activity: Viridian Therapeutics shares were up 13.79% at $20.36 during premarket trading on Monday, according to Benzinga Pro data.
Image via Shutterstock/ grandbrothers
Recent Comments